Baird reiterates Faeth Therapeutics stock rating on clinical data

Baird maintained an Outperform rating and $57.00 price target for Faeth Therapeutics (FTH) on NASDAQ, following a clinical update. The target indicates significant upside potential from the current stock price of $12.21, aligning with the general analyst consensus ranging from $40 to $69. Over the past year, the stock has generated a 142% return, suggesting undervaluation based on Fair Value analysis.

The company presented data from the Phase 2 PIK-201 study of PIKTOR combined with paclitaxel, highlighting competitive efficacy and a favorable safety profile. The trial demonstrated a low incidence of severe side effects, such as Grade 3 or higher stomatitis, and a minimal discontinuation rate. The objective response rate from the study presents an opportunity, given the positive progress-free survival results.

This data supports the outlook for PIKTOR's potential in treating endometrial cancer, with Phase 3 trials already underway. Additionally, the evidence suggests PIKTOR's multi-nodal approach enhances efficacy without increasing toxicity. The firm anticipates positive results for the breast cancer opportunity, with further data expected in 2027.